Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting

[at noodls] – TKM-PLK1 Resulted in Clinical Benefit in 44% of Evaluable Patients Receiving Doses in Effective Range Tekmira to Initiate a Phase II Clinical Trial in Gastrointestinal Carcinoid (Neuroendocrine) Cancer … more

View todays social media effects on TKMR

View the latest stocks trending across Twitter. Click to view dashboard

See who Tekmira is hiring next, click here to view